Palomino Laboratories (PALX) EBIT (2023 - 2025)
Palomino Laboratories recorded quarterly EBIT of -$1.6 million in Q3 2025, down 4414.8% quarter-over-quarter from -$35548.0 in Q2 2025, and down 129958.51% year-over-year from N/an in Q3 2024.
Palomino Laboratories' EBIT history runs 3 years deep, the most recent figure standing at -$1.6 million for Q3 2025.
- In Q3 2025, EBIT fell 129958.51% year-over-year to -$1.6 million; the TTM figure through Sep 2025 stood at -$1.8 million (down 1436.54% YoY), while the FY2024 annual figure was -$140080.0, down 66.89% from the prior year.
- EBIT came in at -$1.6 million for Q3 2025 at Palomino Laboratories, down from -$35548.0 in the prior quarter.
- In the past five years, EBIT ranged from a high of -$1234.0 in Q3 2024 to a low of -$1.6 million in Q3 2025.
- A 3-year average of -$217336.2 and a median of -$35548.0 in 2025 frame the typical range for EBIT.
- Across the five-year window, EBIT soared 97.12% in 2024 and tumbled 129958.51% in 2025, its largest moves.
- Palomino Laboratories' EBIT stood at -$32574.0 in 2023, then plunged by 323.53% to -$137962.0 in 2024, then tumbled by 1063.31% to -$1.6 million in 2025.
- According to Business Quant data, EBIT over the past three periods registered -$1.6 million, -$35548.0, and -$17828.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.60 Mn |
| Jun 30, 2025 | -35,548.00 |
| Mar 31, 2025 | -53,525.00 |
| Dec 31, 2024 | -137,962.00 |
| Sep 30, 2024 | -1,234.00 |
| Jun 30, 2024 | -31,791.00 |
| Mar 31, 2024 | -51,304.00 |
| Dec 31, 2023 | -32,574.00 |
| Sep 30, 2023 | -42,863.00 |